secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVADEL PHARMACEUTICALS PLC (—)
CIK:        0001012477
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001104659-26-013880
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes completes acquisition of Avadel for $21.00 cash + CVR; Avadel delisted from Nasdaq
--------------------------------------------------------------------------------

- Alkermes acquired Avadel for $21.00 per share in cash plus one CVR (potential $1.50 per share).
- Avadel shareholders to receive Total Consideration; trading halted Feb 11, delisting from Nasdaq.
- Avadel terminated ATM agreement with Jefferies and prepaid ~$60.25M to terminate RTW royalty obligations.
- Alkermes financed with ~$750M cash and $1.525B term loans due 2031; expects accretion in 2026.
- CEO Gregory J. Divis, CFO Thomas S. McHugh, COO Susan Rodriguez, GC Jerad G. Seurer, and all directors departed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1012477/000110465926013880/0001104659-26-013880-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1012477/000110465926013880/tm265930d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-013880

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer